Microrandomized trials: An experimental design for developing just-in-time adaptive interventions.

Running Head: Micro-Randomized Trials Micro-Randomized Trials: An Experimental Design for Developing Just-in-Time Adaptive Interventions

Adaptive yield response of winter wheat cultivars across environments in Poland using combined AMMI and

The objective of the paper was to illustrate using and usefulness of a joint AMMI and cluster analyses to assess the grain yield adaptive response of Polish and foreign 31 winter wheat cultivars in a range of 20 environments (locations) and across 3 years (2005-2007) under integrated crop management, using data obtained in the post-registration variety testing trials (called PDO trials), to ide...

Evaluation of Clinical Trials

In a number of important clinical issues such as evaluation of the efficacy or effectiveness of therapeutic or preventive interventions as well as for comparing the harms of interventions, randomized controlled trials (RCTs) provide the highest levels of evidence, either directly or indirectly. It is obvious that critical appraisal of these studies to assess their validity and precision is of p...

Inflation Bias, Time Inconsistency of Monetary and Fiscal Policies and Institutional Quality

In developing countries, weak institutional quality can increase the probability of applying discretionary policies and can have a great impact on their double-digit inflation. Surico (2008) calculated inflation bias, but he considered just monetary policy and he did not pay attention to the institutions. Therefore, we design a model which considers the discretion in monetary and fiscal policie...

Using Adaptive Design to Optimize Product Development at the Program and Portfolio Level

e adoption of an adaptive design strategy across the product development process brings a number of important beneets. ese include increased R&D eeciency, increased R&D productivity and most importantly increased probability of success at phase III. We are all too familiar with the worrying industry statistic that 50% of phase III studies fail and in some therapeutic areas such as oncology the ...